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ABSTRACT
In dementia research, animal models have become
indispensable tools. They not only model aspects of the
human condition, but also simulate processes that occur in
humans and hence provide insight into how disease is
initiated and propagated. The present review discusses two
prominent human neurodegenerative disorders, Alzheimer’s
disease and frontotemporal dementia. It discusses what we
would like to model in animals and highlights some of the
more recent achievements using species as diverse as mice,
fish, flies and worms. Advances in imaging and therapy are
explored. We also discuss some anticipated new models
and developments. These will reveal how key players in the
pathogenesis of Alzheimer’s disease and frontotemporal
dementia, such as the peptide Ab (amyloid b) and the
protein tau, cause neuronal dysfunction and eventually,
neuronal demise. Understanding these processes fully will
lead to early diagnosis and therapy.
Key words: Alzheimer’s disease, amyloid, Caenorhabditis
elegans, Drosophila, frontotemporal dementia, mouse, rat, tau,
TAR DNA-binding protein 43 (TDP-43), transgenic, zebrafish.
INTRODUCTION
The present review is based on a Plenary Lecture given by J.G.
at the 12th ICAD (International Conference on Alzheimer’s
Disease) in Vienna in July 2009.
Animal models have become indispensable in basic and
biomedical research (Go ¨tz and Ittner, 2008). The following
definitions found on the web underscore two important
attributes of a model: the open-source platform Wikipedia
states that an animal model is ‘‘a non-human animal that has
a disease or injury that is similar to a human condition’’
(http://en.wikipedia.org/wiki/Animal_model; accessed 7 July
2009)’’. Another site highlights a second important aspect by
defining an animal model as ‘‘a laboratory animal used in
research that simulates processes comparable to those that
occur in humans’’ (http://science.education.nih.gov/supplements/
nih4/self/other/glossary.htm; accessed 7 July 2009). Applying
these definitions, e.g. to neurodegenerative disorders, illustrates
that models are valuable because they represent a certain stage
of disease and because processes that lead to this stage can be
monitored longitudinally.
In modelling AD (Alzheimer’s disease), the most important
form of dementia, and FTD (frontotemporal dementia), which
in prevalence ratings comes second (Ballatore et al., 2007),
familial forms of these diseases, as well as histopathological
and clinical features in the human patient, provide guidance.
In the present review, first, we discuss the genes that cause
FAD (familial AD) and FTD as remarkably enough a subset of
these genes also encode the proteins within the major lesions
that define the two diseases. In FAD, which accounts for less
than 1% of all cases, autosomal-dominant mutations have
been identified in three genes: APP (amyloid precursor
protein), PSEN1 (presenilin 1) and PSEN2 (presenilin 2)
(Bertram and Tanzi, 2008). APP is a membrane-associated
protein from which the peptide Ab (amyloid b) is derived by
proteolytic cleavage. The presenilins are components of the c-
secretase complex that, together with b-secretase, generates
Ab, while a-secretase activity precludes Ab formation. In
addition to the three FAD genes, a series of susceptibility
genes have been identified in SAD (sporadic AD); these
include APOE (apolipoprotein E) as the most established risk
gene (Bertram and Tanzi, 2008). Very recently, three
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clusterin, PICALM encoding the phosphatidylinositol-binding
clathrin assembly protein and CR1, the complement com-
ponent (3b/4b) receptor 1 (Harold et al., 2009; Lambert et al.,
2009). Compared with AD, FTD is a much more heterogeneous
group of related dementias, which is reflected both by the
types of genes that are mutated and by the proteins that are
deposited. The first mutations identified in FTD were in FTDP-
17 (familial FTD with parkinsonism linked to chromosome 17),
where they were found in the MAPT gene that encodes the
microtubule-associated protein tau (Cruts and Van
Broeckhoven, 2008). This subset of FTD cases is characterized
by tau inclusions (see below). Another subset of familial FTD is
characterized by mutations in the PGRN gene that encodes
the pleiotropic protein progranulin, and in the VCP gene that
encodes valosin-containing protein; these cases are char-
acterized by inclusions of the TDP-43 (TAR DNA-binding
protein 43), a highly conserved hnRNP (heteronuclear
ribonucleoprotein) (Neumann et al., 2006). Finally, mutations
in CHMP2B, encoding chromatin-modifying protein 2B, lead
to FTD in the absence of either tau or TDP-43 inclusions
(Cruts and Van Broeckhoven, 2008). For detailed information,
we refer to http://www.molgen.ua.ac.be/ADMutations and
http://www.molgen.ua.ac.be/FTDMutations as a constantly
updated source of mutations in FAD and FTD, as well as of
the families in which they occur.
Histopathologically, AD is characterized by Ab plaques and
neurofibrillary lesions. Ab in the plaques is fibrillar.
Neurofibrillary lesions contain hyperphosphorylated, fibrillar
aggregates of tau that are found in cell bodies and apical
dendrites as NFTs (neurofibrillary tangles), in distal dendrites
as neuropil threads, and in the abnormal neurites that are
associated with some Ab plaques. Truncation of tau, in
addition to hyperphosphorylation (Chen et al., 2004a), has
been linked to pathogenesis (Horowitz et al., 2004). Tau is
generally perceived as a neuronal protein, with a mainly
axonal localization, but this concept needs to be revisited as
discussed below. In addition to plaques and neurofibrillary
lesions, the AD brain is also characterized by massive neuronal
cell and synapse loss at specific predilection sites (Selkoe,
2002). With regard to the formation of plaques and
neurofibrillary lesions, sporadic cases of AD are not different
from familial cases, whether they carry mutations in APP,
PSEN1 or PSEN2.H e n c e ,t h i sl e dt ot h en o t i o nt h a t
understanding the pathogenesis of familial cases would also
provide insight into the sporadic cases.
In addition to AD, NFTs are also abundantly present in a
significant subset of FTD such as FTDP-17, in which there is an
absence of overt plaques. Another subset of FTD with tau-
negative and ubiquitin-positive lesions, also in the absence of
plaques, has been termed FTLD-U or FTDU-17 (Cruts and Van
Broeckhoven, 2008). Here, TDP-43 has been identified in
ubiquitin-positive inclusions; these have also been found in
sporadic ALS (amyotrophic lateral sclerosis). Similar to tau,
TDP-43 in the aggregates is hyperphosphorylated, ubiquiti-
nated and C-terminally truncated (Neumann et al., 2006).
Both types of protein aggregates can be visualized under the
light microscope either by immunohistochemistry, thioflavin
S or silver impregnation methods such as those developed by
Gallyas and Bielschowsky [as described previously (Ittner et al.,
2008)]. Massive protein aggregation and, in particular, Gallyas
reactivity was one of the defining hallmark aspects of the
human pathology that the early animal models tried to
achieve, but in which they failed: although tau formed
aggregates as the mice aged, NFTs did not develop (Figure 1A)
(Go ¨tz and Ittner, 2008).
Another defining feature of the human pathology is the
characteristic spreading of the hallmark lesions in the AD brain
that, in the case of tau, is subject to little inter-individual
variation and provides a basis for distinguishing six stages: the
transentorhinal stages I and II representing silent cases; the
limbic stages III and IV; and the neocortical stages V and VI
(Braak and Braak, 1991). A similar type of staging has
subsequently been defined for the Ab pathology (Thal et al.,
2002) and is now also available for the Lewy body pathology in
PD (Parkinson’s disease) (Braak et al., 2003). The spreading of
the major histopathological hallmarks of AD, associated with
selective neuronal cell loss, is not well understood at the
cellular and molecular level. The Braak staging implies selective
vulnerability of distinct neuronal populations (Go ¨tz et al.,
2009). This staging is a feature one definitely would like to
recapitulate in animals, as neuronal and synapse lossat specific
predilection sites causes the clinical features that discriminate
AD from FTD (Figure 1B). In the AD brain, atrophy is initiatedin
the hippocampus and entorhinal cortex, followed by the
association cortices and subcortical structures, including
the amygdala and NBM (nucleus basalis of Meynert). The
histopathology is reflected by the clinical features that
characterize AD: early memory deficits that are followed by
a gradual erosion of other cognitive functions (Arnold et al.,
1991). Atrophy in the FTD brain is mainly found in frontal and/
or temporal cortices. Hence, in contrast with AD, FTD is
associated predominantly with behavioural and/or language
impairment, with memory impairment mostly found only late
in disease (Cruts and Van Broeckhoven, 2008). A significant
subset of FTD is characterized by parkinsonism (Figure 1C), an
aspect that has been modelled in animals as outlined below.
A further remarkable aspect one would like to model in
animals is that of the distinct age of onset and disease
duration until death that, e.g. discriminates carriers of PGRN
mutations from those of MAPT mutations (Cruts and Van
Broeckhoven, 2008) (Figure 1D).
In understanding the aetiology of the sporadic cases of AD
and FTD, a lot of hypotheses have been put forward
(addressing an important aspect highlighted by the second
definition we have presented above). These include the
amyloid cascade hypothesis, oxidative stress/mitochondrial
dysfunction, transport/synaptic dysfunction, mitosis failure,
proteasome dysfunction, and stress response and inflam-
mation hypotheses. They have been tackled by a series of
‘omics’ approaches which encompass lipidomics, proteomics,
transcriptomics and genomics (Noorbakhsh et al., 2009).
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The mouse is the major species used in AD and FTD research,
but significant additional insight has been provided from
species such as the roundworm Caenorhabditis elegans, the
fruit fly Drosophila melanogaster, and two types of fish, the
sea lamprey and the zebrafish (Go ¨tz et al., 2007).
As far as rodents are concerned, there are non-transgenic
models available such as the SAM (senescence-accelerated
mice), or chemically induced lesion models, but these lack the
characteristic hallmark lesions of AD (Van Dam and De Deyn,
2006). These have been modelled by transgenesis (Ittner and
Go ¨tz, 2007), almost exclusively in mice, as reviewed recently
(Go ¨tz and Ittner, 2008), although there are a few transgenic
rat models available (Zilka et al., 2006; Koson et al., 2008).
Although the list of strains that were discussed in Go ¨tz and
Ittner (2008) is long, it is still incomplete, since a myriad of
Figure 1 Aspects of AD and FTD one would like to model in animals
Animalmodelshavebecomeindispensable inbasic andbiomedicalresearch.They reproduceaspectsofADandFTD(A–D),butalsoallow
for testing the many hypotheses that have been put forward to determine what exactly causes these diseases (E). In both AD and FTD,
protein aggregation leads to lesions that can be visualized under the light microscope either by immunohistochemistry, by dyes such as
thioflavin S, or by silver impregnation methods such as those developed by Gallyas and Bielschowsky, an aspect to be modelled (as
indicated by the ‘M’) in animals (A). A second aspect is that of the spreading of the key histopathological hallmarks of AD, the Ab
plaques and the tau tangles (NFTs) that has led to the definition of the Braak stages (B). A third is the distinct clinical features such as
memory impairment in AD or parkinsonism that characterizes a subset of FTD cases (C). The fourth is the distinct age of onset and
disease duration that discriminates, e.g. carriers of mutations in the tau-encoding MAPT gene compared with those in the progranulin-
encoding PGRN gene (D) based on data in (Cruts and Van Broeckhoven, 2008). The list of hypotheses in the field is led by the amyloid
cascade hypothesis, but animal models provide support for all proposed hypotheses (E).
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253AD and FTD mouse strains has been generated since the early
1990s and it is impossible to present them all.
However, a few select models may provide a flavour of
what has been achieved so far. Of the many APP mutant mice
that have been generated in the past, strains such as the
PDAPP, J20, APP23 or Tg2576 mice are good representatives
as they are widely used owing to their robust APP/Ab
pathology (Games et al., 1995; Hsiao et al., 1996; Sturchler-
Pierrat et al., 1997; Mucke et al., 2000). Representative
models with NFT formation are strains such as the JNPL3 or
pR5 mice, both of which express P301L mutant tau that
previously has been identified in FTDP-17 (Lewis et al., 2000;
Go ¨tz et al., 2001a). Ab in the above plaque mice is fibrillar, as
is tau in the NFTs of the P301L mutant strains; in both
instances, the histopathology is associated with behavioural
impairment, following assessment of hippocampus- and
amygdala-dependent tasks (Go ¨tz and Ittner, 2008). In
conclusion, the aggregation of both Ab and tau has been
faithfully reproduced in vivo, with the hallmark lesions of AD
and FTD being visible at a light microscopic level. Similarly,
aspects of memory impairment have been reproduced.
The microtubule-associated protein tau is generally
perceived as a neuronal protein, however, tauopathies such
as CBD (corticobasal degeneration) and PSP (progressive
supranuclear palsy) are characterized by a pronounced glial
tau pathology that is often even more pronounced than the
concomitant neuronal pathology (Go ¨tz, 2001; Kurosinski and
Go ¨tz, 2002). The glial tau pathology has been modelled, e.g. in
mice that express wild-type human tau in astrocytes (Forman
et al., 2005). Not only do these mice develop glial lesions that
are remarkably similar to the human pathology, with tufted
astrocytes and astrocytic plaques, but the authors also report
on a focal neuronal degeneration. In other words, a glial
pathology causes a neuronal pathology. The glial lesions were
Gallyas-positive, as in the human patients. Similar inclusions
were obtained by expressing P301L mutant tau in astrocytes;
this again was associated with a neuronal pathology as
evidenced by impaired axonal transport shown for the optic
nerve (Higuchi et al., 2005).
While these studies model tau aggregation and NFT or GFT
(glial fibrillary tangle) formation, other models addressed the
question of how, if at all, the tau aggregates are related to
disease (Go ¨tz et al., 2008a). To this end, a CaMKII (Ca
2+/
calmodulin-dependent protein kinase II) promoter-driven
transactivator system was employed, achieving a 15-fold
overexpression of P301L mutant tau (Ramsden et al., 2005;
Santacruz et al., 2005). This resulted in NFT formation,
neuronal loss and memory impairment. NFT formation was
linked to the appearance of a 64 kDa ‘toxic’ tau species
termed tau*. When tau expression was suppressed after
supplementing the drinking water with doxycycline, this
resulted in a lower, 2.5-fold overexpression. Interestingly,
memory functions recovered, but NFTs continued to accu-
mulate. In more recent work it was shown that, in the young
brain, elevation of the levels of phosphorylated tau species
per se was not sufficient to cause a lasting tau pathology
(Dickey et al., 2009). A CaMKII promoter-driven transactivator
system was also employed to express truncated forms of tau
comprising mainly the C-terminal microtubule-binding
domain. Both a pro- and an anti-aggregation mutant were
generated, with the former resulting in neuronal loss
(Mocanu et al., 2008). An interesting observation was that
human ‘pro-aggregation’ tau co-aggregated with mouse tau,
the possibility of tau forming mixed aggregates being an
issue of discrepancy in the field for quite some time. For
comparison, previous work including a BAC (bacterial
artificial chromosome) transgenic approach combined with
a tau knockout had suggested that endogenous mouse tau is
inhibitory to the aggregation of transgenic human tau
(Andorfer et al., 2003). In the pro-aggregation mouse model,
again, when the mice were fed with doxycycline, tau levels
went down, while NFTs persisted (Mocanu et al., 2008). In
related work in flies, overexpression of both wild-type and
R406W mutant tau was shown to cause premature death,
with mutant tau showing an earlier age of onset (Wittmann
et al., 2001). Cholinergic neurons (a major target of the
cholinergic therapy in AD) were found to be degenerating in
the flies. Interestingly, the tau-associated pathology occurred
in the absence of NFT formation, suggesting that their
formation may not be required for tau to execute its toxic
effects.
Coming back to NFT formation, this has been linked by
several groups to phosphorylation of tau at distinct epitopes
including AT100 (Thr
212/Ser
214) and pS422 (Ser
422) (Go ¨tz and
Nitsch, 2001; Go ¨tz et al., 2001b; Allen et al., 2002; Ferrari
et al., 2003; Guillozet-Bongaarts et al., 2006; Le Corre et al.,
2006; Deters et al., 2008, 2009). The notion that phosphor-
ylation of tau at specific sites is both necessary and sufficient
for tau to form filaments has been recently challenged, again
by work in flies. First it was shown that tau simultaneously
pseudo-phosphorylated at 14 sites (E14 tau) was more toxic
than wild-type tau. Next, these sites were mutated to alanine
residues, both in combination and alone. The analysis of
individual alanine point mutations suggested that tau
phosphorylation sites rather than working ‘in isolation’ act
‘in concert’ in order to promote toxicity (Steinhilb et al.,
2007). However, the final word is not yet spoken, especially as
toxicity may depend on species and cell types. From a
therapeutic perspective, whether general rather than site-
specific phosphorylation needs to be impaired to prevent tau
from aggregating has important implications, as boosting the
activity of more promiscuous phosphatases may be a
preferred strategy compared with reducing the activity of
phospho-site-specific kinases (Iqbal and Grundke-Iqbal,
2008).
Similar to the tau field, with a hunt for what is thought to
be the ‘toxic species’, there is also an ongoing search for the
toxic species in the Ab field [reviewed in (Go ¨tz et al., 2008b;
Yankner and Lu, 2009)]. Here, a dodecameric form of Ab
termed Ab*56 has been identified in mutant APP transgenic
Tg2576 mice that appeared when memory impairment was
initiated and that disappeared when memory decline was
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injected into young recipient rat brains this was shown to
disrupt memory (Lesne et al., 2006). However, in more recent
work, fibrillar Ab was identified as a pathogenic entity that
altered neuronal membrane properties such that there was
hyperexcitability of pyramidal cells, culminating in epilepti-
form activity (Minkeviciene et al., 2009). Moreover, an
analysis of mitochondrial impairment suggests that both
oligomeric and fibrillar species of Ab exert a similar degree of
toxicity (Eckert et al., 2008).
While this addresses memory impairment as the major
clinical feature characterizing AD, another clinical feature,
parkinsonism, that characterizes a significant subset of FTD
cases, has also been modelled in mice. Several mini-gene tau
constructs have been used to establish a series of transgenic
mouse strains, of which one particular strain reproduced tau
accumulation in astrocytes and neurons including these of
the nigro-striatal pathway (Dawson et al., 2007). The rate-
limiting enzyme in dopamine synthesis, TH (tyrosine hydro-
xylase), was found to accumulate in varicosities (axonal
swellings). Furthermore, the mice showed memory and motor
impairment (Dawson et al., 2007). A second model was based
on the identification of the K369I mutation of tau in a
patient with Pick’s disease, an extreme form of FTD (Neumann
et al., 2001). The tau lesions in Pick’s disease (and also in the
brain of this particular patient) show a remarkable feature:
they are Bielschowsky-positive and Gallyas-negative; in
addition tau is phosphorylated at many epitopes but 12E8
(Ser
262/Ser
356). This distinct Pick pathology was reproduced in
the K3 mouse strain that expresses K369I mutant tau (Ittner
et al., 2008). The transgenic mice also model early-onset
parkinsonism (resting tremor, bradykinesia, postural instab-
ility and gait anomalies). They show an increased cataleptic
response to haloperidol and an early, but not late, response to
L-Dopa, with similarities to the efficacy of the treatment in
FTD patients using this form of medication.
IntheK3mice,axonaltransportisimpaired.Indeed inrecent
years, impaired axonal transport emerged as a central
pathomechanism in AD (Stokin et al., 2005; Go ¨tz et al., 2006;
Magnani et al., 2007; Thies and Mandelkow, 2007; Dixit et al.,
2008; Pigino et al., 2009). Impaired axonal transport is
conceptually linked to oxidative stress and mitochondrial
dysfunction: mitochondria are a major organelle that needs to
be efficiently transported along the long processes for neurons
to function and they are a major source of ROS (reactive
oxygen species) (Su et al., 2008; Tatsuta and Langer, 2008). In
the K3 mice, there is a selectively impaired axonal transport of
distinct cargos, such as mitochondria and TH-containing
vesicles (Ittner et al., 2008). This is because a component of
the kinesin motor machinery, the scaffold/adapter protein JIP1
(c-Jun N-terminal kinase-interacting protein 1), is trapped by
elevated tau, preventing it from executing its physiological
function. In a follow-up study a pathological interaction
between tau and JIP1 was also revealed in AD and not control
brain (Ittner et al., 2009). Interestingly, this pathological
interaction requires phosphorylation of tau. Since JIP1 is
involved in regulating cargo binding to kinesin motors, these
findings may, at least in part, explain how hyperphosphory-
lated tau mediates impaired axonal transport in AD and FTD,
before tau starts to aggregate (Ittner et al., 2009). This presents
inhibition of abnormal hyperphosphorylation of tau as a
promising therapeutic target for the development of disease-
modifying drugs (Iqbal and Grundke-Iqbal, 2008).
Another interesting aspect of tau that has recently
emerged is that of the transmission, secretion and spreading
of tau. Using a stereotaxic injection approach (Clavaguera et
al., 2009), a donor brain extract was derived from 6-month-
old NFT-forming P301S mice (Allen et al., 2002) and injected
into brains of 3-month-old ALZ17 mice (Probst et al., 2000;
Go ¨tz and Nitsch, 2001), a (wild-type) tau transgenic strain,
that develops a tau-associated amyotrophy, but fails to
develop NFTs (Clavaguera et al., 2009). The study found that
the donor extract induced NFTs in the recipient brain, a
feature termed ‘transmission’. Secondly, NFT induction was
not confined to the injection site, a feature referred to by the
investigators as ‘spreading’. Finally, insoluble rather than
soluble tau was found to be responsible for these effects
(Clavaguera et al., 2009). In related work, it has been shown
that extracellular tau aggregates can transmit a misfolded
state from the outside to the inside of a cell, similar to prions
(Frost et al., 2009). These features of tau are supported by
work in the sea lamprey, a marine fish characterized by so-
called giant neurons, which can be injected with plasmids
encoding tau expression constructs. Work spanning one and a
half decades support the notion that tau is secreted and
reproduces aspects of the staging that characterizes the tau
pathology (Hall and Cohen, 1983; Hall et al., 2001; Kim et al.,
2009). Similar aspects have been reported for a-synuclein, a
protein with a structure very much like tau, that induced
inclusion formation and neuronal cell death through
interneuronal transmission (Desplats et al., 2009). Taken
together, these data contribute to an understanding of how,
in human disease, Ab and tau impair cellular functions, which
eventually leads to neuronal loss.
Several aspects of the human AD and FTD pathology have
been modelled in the nematode C. elegans (Morcos and
Hutter, 2009). This roundworm has a number of features that
make it a powerful research tool: (i) it is easy to culture as it
feeds on bacteria grown on agar plates; (ii) it reproduces and
develops rapidly: within 3 days it develops from an egg to an
adult worm, with approx. 300 progenies originating from one
self-fertilized hermaphrodite; (iii) its small size allows assays
in microtitre format, studying hundreds of animals in a single
well; (iv) the worm is transparent, which is ideal for the use of
fluorescence markers in vivo; (v) it is a complex multicellular
animal: an adult hermaphrodite has exactly 959 somatic cells
that form different organs, including 302 neurons forming
the nervous system; (vi) it has a short life span of 2–3 weeks,
allowing studies in aged animals within a reasonable time
frame (mice, in comparison, often need to age for 1 year or
even longer before they develop a phenotype); and (vii)
genetic modifications, such as transgenic expression or RNAi
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255(RNA inteference)-mediated gene knockdown are quite easy
compared with other in vivo systems. Furthermore, most
human disease genes and pathways are present in C. elegans
(Kaletta and Hengartner, 2006). This includes the APP
homologue APL-1, a mutation of which results in early larval
lethality (Hornsten et al., 2007). C. elegans has two PSEN
homologues, SEL-12 and HOP-1 (Levitan and Greenwald,
1995; Li and Greenwald, 1997), and a single tau-like protein
called PTL-1 (protein with tau-like repeats) (Goedert et al.,
1996; McDermott et al., 1996)
C. elegans has been successfully used as model organism to
study pathomechanisms in MND (motor neuron disease) and
FTD; e.g. expression of SOD1 (superoxide dismutase 1)
carrying a human pathogenic mutation identified in familial
MND results in severe locomotor deficits in transgenic
C. elegans (Wang et al., 2009). Expression of wild-type
SOD1, however, does not affect motor behaviour. Similarly,
expression of human tau carrying FTD mutations, but not
wild-type tau, in C. elegans results in neurodegeneration with
an accumulation of hyperphosphorylated tau and associated
uncoordinated locomotion (Unc) (Kraemer et al., 2003;
Miyasaka et al., 2005; Brandt et al., 2009). C. elegans is not
capable of producing endogenous Ab. The first published
transgenic model targeted Ab to the body wall of muscle
cells, causing progressive paralysis (Link, 1995). Ab deposition
in another model was associated with oxidative stress (Drake
et al., 2003). A further aspect linked to oxidative stress that is
evident from studies in C. elegans is the similarity between
diabetes mellitus and AD, in particular with regards to the
formation of AGEs (advanced glycation end-products)
(Morcos and Hutter, 2009). Together this demonstrates the
potential of C. elegans as a model organism in AD and FTD
research. The findings obtained in the worm are comple-
mented by studies in Drosophila, that in addition has shown
its potential as a model and a powerful system to screen for
modifiers that either enhance or suppress an AD-associated
pathology (Shulman and Feany, 2003; van de Hoef et al.,
2009).
That farm animals are also attractive as AD models is
illustrated by the recent establishment of a porcine model:
while the transgene was found to be expressed in brain, the
authors speculate that it may take until the age of 1–2 years
until Ab may accumulate in the porcine brain (Kragh et al.,
2009).
THE Ab–TAU AXIS
A central hypothesis in AD research is the amyloid cascade
hypothesis as revisited by Hardy (2006). Animal models were
central in providing support for this hypothesis that claims, in
simplified terms, that an Ab pathology causes a tau pathology
(Figure 2). While initially plaques and NFTs were thought to
be the key players, in recent years the focus has shifted from
these end-stage lesions to the precursors, oligomeric forms of
Ab and soluble forms of tau, as the major (but not exclusive)
culprit. When P301L mutant tau transgenic JNPL3 mice were
crossed with APP mutant Tg2576 mice, this caused a 7-fold
NFT induction, but no increased Ab pathology (Lewis et al.,
2001) (Figure 2A). Similarly, stereotaxic injections of fibrillar
preparations of Ab42 into the hippocampus and somatosen-
sory cortex of P301L tau mutant pR5 mice caused a 5-fold
induction of NFTs in the amygdala, a site which projects to
the CA1 neurons in the hippocampus (Go ¨tz et al., 2001b)
(Figure 2B). The pathology in the amygdala is reflected by an
impairment in amygdala-dependent tasks (Pennanen et al.,
2004, 2006). Injections of Ab42 into wild-type tau transgenic
ALZ17 mice that lack an NFT pathology (Probst et al., 2000)
failed to induce NFTs, suggesting that the toxic effect of Ab is
dependent on a pre-existing tau pathology (Go ¨tz et al.,
2001b).
Subsequently, the so-called 3xtg-AD mice (P301L tau/
APP
sw/PSEN
M146/2 knock-in) were generated that combine
an NFT and plaque pathology (Figure 2C). Their formation
was found to be preceded by synaptic and LTP (long-term
potentiation) deficits (Oddo et al., 2003). The clinical
features were correlated with intraneuronal Ab formation
(Billings et al., 2005), and blocking of Ab was shown to
delay onset and progression of the tau pathology (Oddo
et al., 2008). A stereotaxic approach was used, not by
injecting synthetic Ab preparations (Go ¨tz et al., 2001b), but
by injecting extracts from Ab plaque-forming APP23 mice
into P301L tau mutant JNPL3/B6 mice (Figure 2D). This
induced a tau pathology in areas with a neuronal projection
to the injection site (Bolmont et al., 2007). When the
injections were performed in APP23/JNPL3/B6 mice with
both a plaque and NFT pathology, a more pronounced tau
pathology was induced in areas with a high Ab plaque load
(Bolmont et al., 2007) (Figure 2D).
While this supports the amyloid cascade hypothesis in
mice, there is also a role for tau (Figure 3). Several years ago,
Ab toxicity in primary neuronal cultures was shown to
depend on the presence of tau: wild-type neurons were
found to degenerate when incubated with Ab42 as did tau-
transfected neurons (Figures 3A and 3B). However, primary
neurons derived from tau knockout mice turned out to be
resistant to the toxic effects of Ab (Rapoport et al., 2002)
(Figure 3C). This was translated in vivo by breeding APP
mutant J20 mice on to a tau-knockout background (Roberson
et al., 2007). Most, if not all, APP mutant strains with a robust
Ab plaque pathology are characterized by premature death of
unknown cause (Palop et al., 2007; Minkeviciene et al., 2009;
Palop and Mucke, 2009) (Figure 3D). Roberson and colleagues
reported the remarkable finding that tau reduction amelio-
rates the premature lethality of the J20 mice, increases the
resistance to excitotoxin-induced seizures and prevents
behavioural deficits in the Morris water maze (Roberson et
al., 2007) (Figure 3E).
Taken together, these studies suggest that Ab and tau
contribute synergistically to neurodegeneration in AD (Go ¨tz
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atorial therapy targeting both Ab and tau may be useful
(Golde et al., 2009).
ADVANCES IN ANIMAL IMAGING AND
THERAPY
The preclinical diagnosis of AD depends on neuropsycholo-
gical testing and, increasingly, the use of imaging techniques
and biomarkers in CSF (cerebrospinal fluid) and blood. The
major imaging techniques are PET (positron emission
tomography), CT (computed tomography), MRI (magnetic
resonance imaging) and multiphoton imaging. The field has
been boosted significantly with the development of the PET
tracer PIB (Pittsburgh Compound-B), a thioflavin T derivative.
Using four-dimensional multiphoton imaging of transgenic
mouse brain, PIB was shown to enter the brain extremely
rapidly, Ab was targeted within 1 min, and unbound
florescence cleared within several minutes (Bacskai et al.,
2003). This was soon followed by the first study using PIB in
humans (Klunk et al., 2004). While PET has its undisputed
beauty, there are, however, some major drawbacks, especially
when PET is compared with MRI: it takes around 45 min for
an entire scan (a situation with which healthy people are not
comfortable let alone patients suffering from dementia); a
cyclotron needs to be close to the imaging facility as the t1/2
(half-life) of carbon-20 is only 20 min, and finally, PET is
approx. 50 times as expensive as MRI. Multiphoton imaging
has also been used to determine that plaque formation in
mice can be a surprisingly rapid process, with an Ab plaque
forming within 24 h (Meyer-Luehmann et al., 2008).
Imaging assists in diagnosis, but has its place also in
monitoring the efficacy of therapies. The current treatment
rests on the use of AChE (acetylcholine esterase) inhibitors
and memantine, an NMDA (N-methyl-D-aspartate) receptor
antagonist. The AD major advocacy forum, AlzForum, at the
time of writing this article lists 39 ongoing clinical trials
which include NGF (nerve growth factor), DHA (docosahex-
anoic acid), vitamin A, anti-Ab antibodies, c-secretase
inhibitors, a-secretase activators, oestrogen, natural IgG,
melatonin, a calcium channel agonist, anti-inflammatory
Figure 2 Transgenesis supports the amyloid cascade hypothesis in mice
Crossing P301L tau mutant JNPL3 mice with APP mutant Tg2576 mice causes a 7-fold increased NFT induction, but no increased Ab
pathology (A). Similarly, intracerebral (i.c.) injections of synthetic Ab42 preparations cause a 5-fold induction of NFTs in P301L tau
mutant pR5 mice (B). 3xtg-AD mice (P301L tau/APP
sw/PSEN
M146/2 knockin), that combine an NFT and plaque pathology, show a
prominent role for Ab (C). A stereotaxic approach was used to inject extracts from Ab plaque-forming APP23 mice [and not synthetic
Ab as in (B)] into P301L tau mutant JNPL3/B6 mice, again showing a role for Ab in inducing a tau pathology (D).
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257substances [NSAIDs (non-steroidal anti-inflammatory drugs)],
a nicotinic a7 agonist, statins and the chelator PBT2 (http://
www.alzforum.org).
Many of these therapies have their foundation in animal
work. This includes the vaccination approach, which has been
pioneered by researchers of the biotech company Elan. Using
both an active and passive immunization approach, existing
plaques/Ab pathology could be removed, the formation of
plaques/Ab pathology prevented, and age-dependent learn-
ing deficits reduced or prevented (Schenk et al., 1999; Bard
et al., 2000). In follow-up work in 3xtg-AD mice, which
present with a combined Ab plaque and NFT pathology, these
improvements were correlated with reductions in soluble Ab
and tau (Oddo et al., 2006). The last years have seen many
modifications of the initial approach that has been tested in
mice, using different routes of administration, changes to the
peptide, alterations to the adjuvans, a DNA vaccination
strategy, or as has been done recently, by coupling of Ab to
retro-particles (Bach et al., 2009). As the brain is generally
conceived to be immune-privileged, the efficacy of the Ab-
targeted immunization approach came as a surprise, most
likely also for those who had initiated the first vaccinations.
In the case of tau, one would think that efficacy would be
even more difficult to achieve as, different from Ab, tau is
intracellular and hence, at least at first sight, not seen by the
immune system. However, it seems as if tau is presented as an
antigen or released into the extracellular space, because
immunization of tau transgenic mice with the PHF1 phospho-
tau-peptide (which contains the phospho-sites Ser
396 and
Ser
404) causes a reduction of aggregated tau levels, a shift
from the insoluble to the soluble pool of tau and a slowing of
the progression of an NFT-related motor phenotype (Asuni
et al., 2007).
The fact that our way of life affects our health in old age
comes as no surprise. Several recent studies in mice address
stress, diet, exercise and environmental enrichment. One of the
earliest studies addressing the impact of an enriched
environment used the APP
sw/PS1DE9 mice with a plaque
pathology. Housing of the mice was in large cages and they
were given running wheels, coloured tunnels, toys and
chewable material to play with. This caused reductions in Ab
levels and plaque load; furthermore, levels of the Ab-
degrading enzyme neprilysin and of learning-related genes
wereup-regulated(Lazarovetal.,2005).Whenplaque-forming
Figure 3 Critical role for tau in Ab toxicity
That tau is critical for Ab-mediated toxicity, has been shown in primary neuronal cultures: wild-type (wt) neurons (A) degenerated
when incubated with Ab42, as did tau-transfected neurons (C). Primary neurons derived from tau knockout (KO) mice, however, were
resistant to the toxic effects of Ab (B). This has been translated in vivo. Most, if not all, APP mutant strains with a robust Ab plaque
pathology are characterized by premature death of unknown cause. This includes APP mutant J20 mice (D). By crossing these on to a
hetero- or homo-zygous tau knockout background many clinical features could be ameliorated (E).
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EGCG (epigallocatechin gallate), this had similar effects: again,
Ab levels and plaque load were reduced, and this was
dependent on the up-regulation of the a-secretase ADAM (a
disintegrin and metalloproteinase) 10 (Rezai-Zadeh et al.,
2005; Obregon et al., 2006).
The deacetylase Sir2 is a critical regulator of the ageing
process. SIR2 is a longevity gene and SIRT1 is its human
homologue. Resveratrol, a well-known active compound in
red wine, activates SIRT1. When p25 transgenic mice [p25 is
an activator of the kinase cdk5 (cyclin-dependent kinase 5)]
were intra-hippocampally injected with SIRT1 lentiviruses,
this protected the p25 mice from neurodegeneration (Kim
et al., 2007). Finally, the typical Western diet is not well
balanced with a ratio of unsaturated fatty acids of n23
(omega-3)/n26 (omega-6)51:24, whereas the ideal diet
would be 1:5. When Tg2576 mice were fed with n23, this
reduced Ab levels by 70% and the plaque burden by 40% (Lim
et al., 2005). Taken together this indicates a role for
environmental factors in the progression of AD.
Both tau and APP are phospho-proteins, and phosphoryla-
tion is regulated by a balanced interplay of kinases and
phosphatases; hence, numerous molecules which interfere
with their function have been tested in vitro and in animals
(Pei et al., 2008). Very recently, a zebrafish model has been
established which reproduced tau hyperphosphorylation, NFT
formation, and neuronal and behavioural disturbances, as
well as cell death. Of the many inhibitors of the kinase GSK3b
(glycogen synthase kinase 3b) tested in the fish model,
AR-534 turned out to reduce tau hyperphosphorylation
in vivo (Paquet et al., 2009).
Another strategy is the targeting of phosphatasesas has been
suggested recently (Iqbal and Grundke-Iqbal, 2008). Here, PP2A
(protein phosphatase 2A) is particularly attractive, as instead of
modulating general catalytic activity it may be possible to
activate specifically the oneof its many regulatory subunits that
confers specificity for tau as a substrate (Kins et al., 2001; Schild
et al., 2006). Together this presents a strategy that modulates
either kinases or phosphatases as an attractive therapeutic
approach (Iqbal and Grundke-Iqbal, 2008).
WHAT HAVE WE ACHIEVED SO FAR AND
WHAT DOES THE FUTURE HOLD?
What has been achieved so far? Depending on how much
emphasis is placed on the different aspects of AD modelling
in animals (symbolized by the ‘M’ in Figure 4), the balance of
Figure 4 Modelling in animals and what has been achieved so far
Depending on how much weight we put on the different aspects of AD modelling (symbolized by the ‘M’) in animals the balance of
‘achievement’ will vary. The distribution is not meant to be taken at face value, but thought to provide an idea of which aspects of
the human disease need further development. Protein aggregation has been very faithfully modelled in animals, as have aspects
of behavioural impairment. Support has been provided for all hypotheses proposed for AD and FTD. Some insight has been achieved
into the molecular mechanisms of how soluble tau and the different assembly states of Ab cause and initiate cellular demise, but a
real understanding is still lacking. The more we move to the right, the less has been authentically modelled. There are indeed aspects
which, for obvious reasons, cannot be modelled in animals at all, such as the language variants of FTD.
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259‘achievement’ will vary. The difference in emphasis is not
meant to be taken at face value, but should rather provide an
idea for further opportunities of advancement.
In discussing what the future holds, we would like to
highlight two selected aspects, selective vulnerability and the
functional domains of APP. Selective vulnerability charac-
terizes AD and FTD but the cellular and molecular basis of it is
not at all understood (Go ¨tz et al., 2009). In AD, both the Braak
staging outlined above (Braak and Braak, 1991) and the
distribution of NFTs reflect selective vulnerability.
Interestingly, in the AD brain some areas are spared from
degeneration until very late in disease. Also, in the basal
forebrain all neurons that die appear to contain NFTs (Cullen
and Halliday, 1998), whereas in the CA1 region, up to 20% of
the neuronal loss cannot be explained by NFT formation,
suggesting that modes of death differ (Gomez-Isla et al.,
1997; Kril et al., 2002; Giannakopoulos et al., 2003). How can
transgenic mouse models be exploited to dissect selective
vulnerability and identify genes and proteins that either
protect from degeneration or confer an increased risk? This is
exemplified for two selected mouse models, one character-
ized by memory impairment and the other in addition by
parkinsonism (Figure 5): rTg(tauP301L)4510 mice with an
inducible and hence very strong P301L mutant tau expression
are characterized by massive brain weight loss and gross
atrophy of the forebrain (Santacruz et al., 2005). By 5.5
months, 60% of CA1 hippocampal pyramidal neurons are lost,
and by 8.5 months only 23% remain (Santacruz et al., 2005).
K3 mice are characterized by loss of TH-positive, K369I tau-
expressing neurons in the substantia nigra, long after the first
clinical symptoms become apparent (Ittner et al., 2008, 2009).
Interestingly, this loss is only partial, with 60% of the TH
neurons lost by 24 months of age. What protects a subset of
morphologically indistinguishable neurons within this brain
area from cell death while others degenerate?
We previously used the tools of functional genomics to
dissect pathogenic mechanisms, including mitochondrial
dysfunction and AGE formation that not only operate in
the transgenic mouse but also in human diseased brain (Chen
et al., 2004b; Hoerndli et al., 2004; David et al., 2005a, 2005b;
Hoerndli et al., 2005; David et al., 2006; Hoerndli et al., 2007).
Functional genomics not only assists in dissecting disease
mechanisms, but also emerges as a powerful tool in
identifying cell-type-specific gene expression, which ulti-
mately may be useful to understand selective vulnerability. In
an impressive study, Sugino and colleagues used four GFP
(green fluorescent protein)-expressing transgenic mouse lines
to obtained eleven fluorescently labelled neuronal popula-
tions from different brain areas (Sugino et al., 2006). They
triturated the neurons and by an elaborate panning process,
manually isolated between 30 and 120 neurons from each
brain area that they had characterized previously using
current-clamp recordings. The subsequent analysis of the
transcriptomic profile allowed them to construct a taxonomic
tree that showed clear distinctions between neuronal cell
types such as cortical interneurons and projection neurons
(Sugino et al., 2006). We believe that crossing GFP-marked
mice with AD or FTD mouse models such as those described
above should allow identification of genes that confer
susceptibility to or protection from neuronal degeneration.
Ultimately, these genes can be reintroduced into the germline
of mice for a functional validation (Figure 5).
Another aspect which is likely to receive more attention
in the future is the realization that in pathogenesis func-
tional domains of APP, other than Ab, may have a role. APP
overexpression causes an axonal transport defect (Stokin
et al., 2005, 2008). However, by fusing the Ab domain with
the BRI protein, it could be shown that the APP-induced
axonal defects are not caused by Ab as one might have
expected (Stokin et al., 2008). Similarly, in more recent work,
APP was found to be a ligand of the DR (death receptor).
Binding of an N-terminal APP fragment was further shown to
trigger neuronal degeneration, leading to the notion that an
extracellular APP fragment, in addition to Ab, contributes to
AD (Nikolaev et al., 2009).
Therefore it is obvious that more transgenic models are
needed to dissect the role of the different functional domains
of APP. Certainly, for any gene implicated in AD and FTD,
more sophisticated cell-type-specific and/or inducible trans-
genic systems need to be developed. Animals need to be
humanized by using BAC-transgenic approaches as has been
done previously (Andorfer et al., 2003). More tools need to be
developed, such as additional conformation- and epitope-
specific antibodies, to better characterize and isolate toxic
species (Habicht et al., 2007; Glabe, 2008). Finally, insight
gained from the various animal species needs to be fully
Figure 5 Selective vulnerability examined in two mouse models with
neuronal loss
Selective vulnerability characterizes two selected mouse strains, one
characterized by memory impairment [rTg(tauP301L)4510 line] and the other,
in addition, by parkinsonism (K369I tau mutant K3 strain). The
rTg(tauP301L)4510 mice lose 60% of CA1 hippocampal pyramidal neurons
by 5.5 months, and only 23% remain by 8.5 months. In the K3 mice, loss of TH
neurons is also only partial, with 60% lost by 24 months of age. What
protects a subset of morphologically indistinguishable neurons within the
respective brain area from cell death while others degenerate?
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limitations, but also the complementary potential. In
conclusion, animal models will continue to be an important
tool in AD and FTD research. While the mouse is likely to
remain the major species, a larger contribution of inverteb-
rate models can be foreseen.
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